Orphan medicinal products (OMPs) are targeted at the diagnosis, prevention or treatment of rare diseases and have a special status in European law. This status brings incentives for pharmaceutical companies to invest in OMP development. The goal of the legislation is to encourage the development of more treatments for life-threatening rare disorders, but increased availability of OMPs raises important issues surrounding the public funding of very expensive treatments by national health services. In this article we review OMPs and the incentives for their development and discuss the challenges presented by funding these treatments.

译文

孤儿药品 (OMPs) 针对罕见疾病的诊断,预防或治疗,在欧洲法律中具有特殊地位。这种状态为制药公司投资OMP开发带来了动力。该立法的目标是鼓励为危及生命的罕见疾病开发更多的治疗方法,但是omp的可用性增加引发了围绕国家卫生服务机构为非常昂贵的治疗提供公共资金的重要问题。在本文中,我们回顾了omp及其发展的诱因,并讨论了资助这些治疗带来的挑战。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录